DeCure for Mitochondrial DNA depletion syndrome 14 (cardioencephalomyopathic type)
DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for mitochondrial DNA depletion syndrome 14 (cardioencephalomyopathic type) — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMitochondrial DNA depletion syndrome 14 (cardioencephalomyopathic type) maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for mitochondrial dna depletion syndrome 14 (cardioencephalomyopathic type) is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Mitochondrial DNA depletion syndrome 14 (cardioencephalomyopathic type) is a progressive disorder defined by low mtDNA copy number, caused by mutations in nuclear genes that regulate mitochondrial function. The 2022 review lists TK2, FBXL4, TYPM, and AGK as known associated genes, and notes that newer studies have identified additional mutation loci. The syndrome involves deficient ATP production, reactive oxygen species generation, and calcium overload, and is linked to cardiac disease. No specific treatment data for this syndrome are given in either abstract.
The 1999 review discusses mitochondrial biology and the shift toward treating mitochondrially based disorders, but it covers archetypal mitochondrial diseases and neurodegenerative conditions in general. It reviews treatment prospects for neuroprotection without providing any concrete outcomes, survival figures, or response rates for any drug or intervention. No drug names, trial results, or patient numbers appear in any of the three abstracts.
The third abstract is an interview transcript that repeats the same introductory material on mitochondrial structure and function found in the 2022 review. It adds no new clinical data, no experimental results, and no mention of any therapeutic agent.
What is still missing: any clinical trial testing a specific drug for mitochondrial DNA depletion syndrome 14, any patient-level data on survival or disease progression, any evidence of biomarker-driven patient stratification, and any funding commitment to a dedicated treatment study for this rare cardioencephalomyopathic form.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Frontiers in Cardiovascular Medicine · 2022 · 14 citations · open access
Mitochondrial DNA Depletion Syndrome and Its Associated Cardiac Disease
AbstractMitochondria is a ubiquitous, energy-supplying (ATP-based) organelle found in nearly all eukaryotes. It acts as a “power plant” by producing ATP through oxidative phosphorylation, providing energy for the cell. The bioenergetic functions of mitochondria are regulated by nuclear genes (nDNA). Mitochondrial DNA (mtDNA) and respiratory enzymes lose normal structure and function when nuclear genes encoding the related mitochondrial factors are impaired, resulting in deficiency in energy production. Massive generation of reactive oxygen species and calcium overload are common causes of mitochondrial diseases. The mitochondrial depletion syndrome (MDS) is associated with the mutations of mitochondrial genes in the nucleus. It is a heterogeneous group of progressive disorders characterized by the low mtDNA copy number. TK2, FBXL4, TYPM , and AGK are genes known to be related to MDS. More recent studies identified new mutation loci associated with this disease. Herein, we first summarize the structure and function of mitochondria, and then discuss the characteristics of various types of MDS and its association with cardiac diseases.
Entrevista a Juan José Azcárate, Consejero delegado de Centro para la Cultura y el Conocimiento(CCC)
AbstractMitochondria is a ubiquitous, energy-supplying (ATP-based) organelle found in nearly all eukaryotes. It acts as a "power plant" by producing ATP through oxidative phosphorylation, providing energy for the cell. The bioenergetic functions of mitochondria are regulated by nuclear genes (nDNA). Mitochondrial DNA (mtDNA) and respiratory enzymes lose normal structure and function when nuclear genes encoding the related mitochondrial factors are impaired, resulting in deficiency in energy production. Massive generation of reactive oxygen species and calcium overload are common causes of mitochondrial diseases. The mitochondrial depletion syndrome (MDS) is associated with the mutations of mitochondrial genes in the nucleus. It is a heterogeneous group of progressive disorders characterized by the low mtDNA copy number. <i>TK2, FBXL4, TYPM</i>, and <i>AGK</i> are genes known to be related to MDS. More recent studies identified new mutation loci associated with this disease. Herein, we first summarize the structure and function of mitochondria, and then discuss the characteristics of various types of MDS and its association with cardiac diseases.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
